Array BioPharma Inc. drugs
3 results
Braftovi (encorafenib)
(Encorafenib)Array BioPharma Inc.
Braftovi (encorafenib)
(Encorafenib)Array BioPharma Inc.
Usage: BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer (mCRC), and metastatic non-small cell lung cancer (NSCLC) with BRAF V600E or V600K mutations when used with specific combinations. It is not meant for wild-type BRAF tumors.
Mektovi (binimetinib)
(BINIMETINIB)Array BioPharma Inc.
Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E or V600K mutations, as confirmed by FDA-approved tests.